Lucid Capital initiated coverage of MeiraGTx (MGTX) with a Buy rating and $50 price target MeiraGTx is developing next-generation, genetic medicines to potentially unlock cures in chronic diseases, the analyst tells investors in a research note. The firm says the company is “providing a toolbox to pharma.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGTX: